Edgewise Therapeutics, Inc. (EWTX) Stock Price & Analysis
Edgewise Therapeutics, Inc. (EWTX) closed at USD 39.99 on Thursday, October 22, 2026, up 0.86% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 39.65; the Oct 22, 2026 session ranged USD 38.36–40.69 on volume of 1,337,723 shares. Market capitalization is $4.34B, with a 52-week range of USD 14.85–48.51 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/EWTX.md
Key facts (EWTX)
- Analysts: Buy (mean 1.93 on a 1–5 scale) (14 analysts), mean target USD 52.62 (range 36–66).
- Total return with dividends: 1Y +164.8% vs S&P 500 +14.9%; 5Y +139.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.51, revenue estimate $119M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EWTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$43.2M | -$71.7M | -$114M | -$159M | -$191M | -$219M |
| Net income | -$42.8M | -$67.6M | -$100M | -$134M | -$168M | -$197M |
| EPS (diluted) | -$1.14 | -$1.26 | -$1.57 | -$1.45 | -$1.63 | — |
| Free cash flow | -$34.2M | -$58.2M | -$97.7M | -$110M | -$144M | -$159M |
| Cash + short-term investments | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (EWTX)
P/B 9.7x · FCF yield -3.66% · Earnings yield -4.54%
Analysts (EWTX)
Consensus Buy (mean 1.93 on a 1–5 scale), 14 analysts; mean target USD 52.62 (low 36, high 66).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiated | Outperform | |
| 2026-09-21 | HC Wainwright & Co. | Target raised | Buy | $45 → $57 |
| 2026-08-20 | JP Morgan | Target raised | Overweight | $53 → $60 |
| 2026-08-11 | Goldman Sachs | Target raised | Neutral | $32 → $36 |
| 2026-07-20 | Evercore ISI Group | Target raised | Outperform | $45 → $55 |
| 2026-07-09 | Oppenheimer | Initiated | Outperform | $51 |
| 2026-07-06 | Guggenheim | Target raised | Buy | $41 → $51 |
Total return (dividends reinvested) (EWTX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +164.8% | +139.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +165.7% | +19.0% |
| Volatility (annualized) | 72.2% | 78.1% |
| Max drawdown | -25.0% (Jul 2026→Oct 2026) | -73.0% (Nov 2021→Nov 2023) |
EWTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.51 | $1.13 | +121.9% | $119.2M | 11 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.31 | +23.5% | $9.6M | 13 |
| Current fiscal year (ends Dec 2026) | $2.27 | $-0.23 | -1070.8% | $128.8M | 11 |
| Next fiscal year (ends Dec 2027) | $-1.77 | $-1.47 | +20.4% | $39.2M | 12 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 39.99 |
|---|---|
| Change | ▲ 0.86% (up) |
| Previous Close | USD 39.65 |
| Open | USD 39.11 |
| Day Range | USD 38.36 – 40.69 |
| 52-Week Range | USD 14.85 – 48.51 |
| Volume | 1,337,723 shares |
| Market Cap | $4.34B |
| Exchange | NMS |
Technical Analysis (EWTX)
Nexqual's technical model rates EWTX "NEUTRAL" based on 2 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.37 (neutral) |
| vs SMA50 | Below (USD 41.92) |
| MACD | -0.87 (negative) |
Analyst Ratings (EWTX)
Wall Street analysts rate EWTX "Buy" based on 14 analysts, with a mean price target of USD 52.62 (range USD 36–66), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 52.62 |
| High Target | USD 66 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 12 / 2 / 0 |
Earnings (EWTX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.51 |
| Revenue Estimate | $119.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.53 vs est -0.47 ▼ miss |
| 2026-03-31 | USD -0.46 vs est -0.49 ▲ beat |
| 2025-12-31 | USD -0.47 vs est -0.44 ▼ miss |
| 2025-09-30 | USD -0.39 vs est -0.4 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (EWTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -38.03% |
| Debt / Equity | 0.01 |
| Current Ratio | 16.24 |
| Total Cash | $460.71M |
| Total Debt | $3.59M |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (EWTX)
Nexqual rates Edgewise Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $461M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$144M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -38%, ROA -25.0% |
Ownership (EWTX)
| Insider Ownership | +0.49% |
|---|---|
| Institutional Ownership | +112.31% |
| Shares Outstanding | 108.60M |
| Float | 74.27M |
| Short % of Float | +14.56% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (EWTX)
Edgewise Therapeutics, Inc. is led by Kevin Koch, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| President, CEO & Director | Kevin Koch |
|---|---|
| Co-Founder & Independent Chairman | Peter A. Thompson FACP |
| Co-Founder & Independent Director | Badreddin Edris |
| Co-Founder, Chief Scientific Officer & Director | Alan J. Russell |
| Chief Financial Officer | Michael P. Nofi |
Major Backers & Investors (EWTX)
Notable institutional backers of Edgewise Therapeutics, Inc. include Orbimed Advisors LLC., Paradigm Biocapital Advisors LP, RA Capital Management, L.P., according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbimed Advisors LLC. | 14.29% |
| Paradigm Biocapital Advisors LP | 9.41% |
| RA Capital Management, L.P. | 7.73% |
| Jupiter Topco LLC | 5.59% |
| FMR, LLC | 5.05% |
| Novo Holdings A/S | 4.93% |
| Driehaus Capital Management, LLC | 4.35% |
| Perceptive Advisors Llc | 4.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.08% |
| Vanguard Group | 3.55% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt